HUE062000T2 - BCL-2 inhibitor új sója, vonatkozó kristályforma, ezek elõállítási eljárása és ezeket tartalmazó gyógyszerkészítmények - Google Patents

BCL-2 inhibitor új sója, vonatkozó kristályforma, ezek elõállítási eljárása és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUE062000T2
HUE062000T2 HUE19800947A HUE19800947A HUE062000T2 HU E062000 T2 HUE062000 T2 HU E062000T2 HU E19800947 A HUE19800947 A HU E19800947A HU E19800947 A HUE19800947 A HU E19800947A HU E062000 T2 HUE062000 T2 HU E062000T2
Authority
HU
Hungary
Prior art keywords
same
bcl
inhibitor
preparing
pharmaceutical compositions
Prior art date
Application number
HUE19800947A
Other languages
English (en)
Inventor
Michael Lynch
Frederic Villard
Patrick Mouchet
Pascal Taulelle
Ludovic Masson
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of HUE062000T2 publication Critical patent/HUE062000T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE19800947A 2018-10-31 2019-10-30 BCL-2 inhibitor új sója, vonatkozó kristályforma, ezek elõállítási eljárása és ezeket tartalmazó gyógyszerkészítmények HUE062000T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18306430 2018-10-31

Publications (1)

Publication Number Publication Date
HUE062000T2 true HUE062000T2 (hu) 2023-09-28

Family

ID=64270773

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19800947A HUE062000T2 (hu) 2018-10-31 2019-10-30 BCL-2 inhibitor új sója, vonatkozó kristályforma, ezek elõállítási eljárása és ezeket tartalmazó gyógyszerkészítmények

Country Status (38)

Country Link
US (2) US20210355108A1 (hu)
EP (1) EP3873894B1 (hu)
JP (2) JP2022506137A (hu)
KR (1) KR20210092750A (hu)
CN (1) CN112969693A (hu)
AR (1) AR116921A1 (hu)
AU (1) AU2019370926B2 (hu)
BR (1) BR112021007194A2 (hu)
CA (1) CA3117559C (hu)
CL (1) CL2021000947A1 (hu)
CO (1) CO2021005077A2 (hu)
CR (1) CR20210211A (hu)
CY (1) CY1126057T1 (hu)
DK (1) DK3873894T3 (hu)
DO (1) DOP2021000074A (hu)
EA (1) EA202191143A1 (hu)
ES (1) ES2943511T3 (hu)
FI (1) FI3873894T3 (hu)
GE (2) GEP20237494B (hu)
HR (1) HRP20230563T1 (hu)
HU (1) HUE062000T2 (hu)
IL (1) IL282565A (hu)
JO (1) JOP20210072A1 (hu)
LT (1) LT3873894T (hu)
MA (1) MA54063B1 (hu)
MX (1) MX2021004934A (hu)
MY (1) MY202547A (hu)
NI (1) NI202100025A (hu)
PE (1) PE20211503A1 (hu)
PH (1) PH12021550790A1 (hu)
PL (1) PL3873894T3 (hu)
PT (1) PT3873894T (hu)
RS (1) RS64236B1 (hu)
SG (1) SG11202103594XA (hu)
SI (1) SI3873894T1 (hu)
TW (1) TWI791916B (hu)
WO (1) WO2020089281A1 (hu)
ZA (1) ZA202102783B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4088896B1 (en) 2019-09-27 2025-01-22 Shanghai Flyco Electrical Appliance Co., Ltd. Electric shaver, handheld household electrical appliance, electric shaver system, and control method
CA3190276A1 (en) 2020-07-31 2022-02-03 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
KR20230160303A (ko) 2021-03-24 2023-11-23 르 라보레또레 쎄르비에르 ５－｛５－클로로－２－[(3s)－３－[(모르폴린－４－일)메틸]－３,４－디하이드로이소퀴놀린－２(１ｈ)－카르보닐]페닐｝－１,２－디메틸－１ｈ－피롤－３－카르복실산 유도체의 신규한 합성 방법 및 약학적 화합물의 생산을 위한 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
WO2006073292A1 (en) * 2005-01-06 2006-07-13 Cj Corporation Inorganic acid salts of sibutramine
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
CN101962387B (zh) * 2010-09-13 2013-01-30 成都雅途生物技术有限公司 一种新结晶形态的氯吡格雷硫酸氢盐及其制备方法
CN103664753B (zh) * 2012-09-04 2017-04-26 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2016248376B2 (en) * 2015-04-15 2020-10-08 Beone Medicines I Gmbh Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore

Also Published As

Publication number Publication date
CY1126057T1 (el) 2023-11-15
JOP20210072A1 (ar) 2023-01-30
HRP20230563T1 (hr) 2023-08-18
SI3873894T1 (sl) 2023-08-31
US20210355108A1 (en) 2021-11-18
RS64236B1 (sr) 2023-06-30
EP3873894A1 (en) 2021-09-08
US20240417390A1 (en) 2024-12-19
PE20211503A1 (es) 2021-08-11
AU2019370926A1 (en) 2021-05-20
DK3873894T3 (da) 2023-06-06
AR116921A1 (es) 2021-06-30
PH12021550790A1 (en) 2021-10-25
WO2020089281A1 (en) 2020-05-07
AU2019370926B2 (en) 2024-11-07
EP3873894B1 (en) 2023-03-22
JP2025028968A (ja) 2025-03-05
LT3873894T (lt) 2023-06-26
TWI791916B (zh) 2023-02-11
CR20210211A (es) 2021-05-25
TW202033517A (zh) 2020-09-16
FI3873894T3 (fi) 2023-06-07
CL2021000947A1 (es) 2021-11-19
GEP20237494B (en) 2023-04-10
KR20210092750A (ko) 2021-07-26
SG11202103594XA (en) 2021-05-28
CO2021005077A2 (es) 2021-09-20
DOP2021000074A (es) 2021-07-22
ES2943511T3 (es) 2023-06-13
CN112969693A (zh) 2021-06-15
MA54063B1 (fr) 2023-06-28
BR112021007194A2 (pt) 2021-07-20
JP2022506137A (ja) 2022-01-17
ZA202102783B (en) 2022-10-26
PT3873894T (pt) 2023-04-28
CA3117559A1 (en) 2020-05-07
EA202191143A1 (ru) 2021-09-10
NI202100025A (es) 2021-08-24
MX2021004934A (es) 2021-06-08
MY202547A (en) 2024-05-07
IL282565A (en) 2021-06-30
NZ775308A (en) 2024-04-26
GEAP202215620A (en) 2022-11-10
PL3873894T3 (pl) 2023-07-31
MA54063A (fr) 2021-09-08
CA3117559C (en) 2023-09-26

Similar Documents

Publication Publication Date Title
ZA202102783B (en) Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
IL289763A (en) Compounds, pharmaceutical compounds and methods for preparing compounds and their use
ZA201907687B (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
HUE052049T2 (hu) Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
ZA201901717B (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
PH12017501641A1 (en) Acetate salt of buprenorphine and methods for preparing buprenorphine
IL289453B2 (en) Process for preparing ridinilazole and its crystalline forms
IL319797B1 (en) Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof
PT3632436T (pt) Composição farmacêutica compreendendo sais de lenvatinib
HUE059444T2 (hu) Morfolinszármazék sója és ennek kristályformája, valamint ezek elõállítási eljárása, gyógyszerkészítménye és alkalmazása
SG11202012620SA (en) Amino-pyrimidonyl derivatives, a process for their preparation and pharmaceutical compositions containing them
IL285453B2 (en) Preparations for making sweets
GB201918401D0 (en) Novel crystalline forms of Flufenacet, methods for their preparation and use of the same
GB201918391D0 (en) Novel crystalline forms of flufenacet, methods for their preparation and use of the same
SG11202111558VA (en) Crystalline form of compound, method for preparing the same, pharmaceutical composition and use
IL290215A (en) A process for the preparation of crystalline form ii of sotagliflozin
IL290214A (en) A continuous process for the preparation of crystalline form ii of sotagliflozin
WO2017029642A3 (en) Novel polymorphs of dolutegravir and salts thereof
HUP1800397A2 (en) Process for the preparation of lumateperone and salts thereof
EP3889157C0 (en) SALT AND CRYSTALLINE FORM OF A FUROPYRIMIDINE COMPOUND AND THEIR PHARMACEUTICAL USE
IL262490A (en) Lomacaptor complexes and their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them
IL262489A (en) Complexes of ivacaptor and its salts and their history, a process for their preparation and pharmaceutical preparations containing them
HUP1800089A2 (en) Process for the preparation of the b polymorph form of treprostinil-diethanol-amine salt
HK40005617A (en) Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them